Sun Pharmaceutical Industries will hold a Board meeting on October 12, 2026, to approve the issuance of non-convertible debentures worth up to ₹15,000 crore to fund a bridge loan for acquiring Organon & Co.
Sun Pharmaceutical Industries will hold a Board meeting on October 12, 2026, to approve the issuance of non-convertible debentures worth up to ₹15,000 crore to fund a bridge loan for acquiring Organon & Co.
<iframe src="https://hindustansphere.com/embed/cluster/1231757f759fc315d9320b4b63d67f204c1f9cdb" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October"></iframe>
